PharVision Advisers’s Dover DOV Stock Holding History

PharVision Advisers’s Portfolio DOV Stock Details DOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,435	Closed	-$239K	–	763
2025 Q3	$239K	Buy	1,435 +199	+16%	+$35.7K	0.13%	364
2025 Q2	$226K	Sell	1,236 -57	-4%	-$9.92K	0.33%	165
2025 Q1	$227K	Buy	+1,293	New	+$249K	0.32%	160

Other funds holding DOV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PharVision Advisers's DOV Position: Q4 2025 in Review

PharVision Advisers sold out of Dover (DOV) in Q4 2025, closing a stake of 1,435 shares — an estimated $239K sold.

PharVision Advisers first reported a position in DOV in Q1 2025 and held it in 3 quarters. The position peaked at $239K in Q3 2025. 1,111 funds tracked by Wall St. Rank hold DOV as of Q4 2025.

PharVision Advisers reported no remaining Dover position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,435 Dover shares in Q4 2025, an estimated $239K.
PharVision Advisers first reported a position in Dover in Q1 2025 and held it in 3 quarters.
PharVision Advisers's Dover position peaked at $239K in Q3 2025.
1,111 funds tracked by Wall St. Rank held Dover as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.